Although More-Expensive Atypical Antipsychotics Will Drive the Schizophrenia Drug Market, they Will Face Tough Competition from Generics

Antipsychotics to Start Losing Patent Protection by 2007, According to a New

Study from Decision Resources

Jun 16, 2004, 01:00 ET from Decision Resources, Inc.

    WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, Inc., one of
 the world's leading research and advisory firms focusing on pharmaceutical and
 health care issues, finds that although more-expensive atypical antipsychotics
 such as Eli Lilly's Zyprexa, Otsuka Pharmaceutical/Bristol-Myers Squibb's
 Abilify, Janssen's Risperdal, AstraZeneca's Seroquel, and Pfizer's Geodon will
 drive the schizophrenia drug market during the period 2003-2013, they will
 face generic competition by the end of this time frame. According to a new
 Pharmacor study entitled Schizophrenia, generic erosion will exact a heavy
 toll on the market because these antipsychotics lose patent protection in 2007
 or later.
     "Generics will have the greatest impact on the U.S. market, which is the
 largest and most receptive market for generics," said Michelle Grady, analyst
 at Decision Resources. "This market will experience a 3.0% annual decline over
 the period 2008-2013. The launch of depot formulations of atypical
 antipsychotics and a few other less promising emerging agents will be the only
 protection against a more precipitous decline."
     About Schizophrenia
     Virtually all patients require drug therapy to cope with the symptoms of
 schizophrenia, but as many as 30% of schizophrenia patients are refractory to
 available drugs. Furthermore, although most physicians agree that current drug
 therapy adequately addresses the positive symptoms of schizophrenia, these
 same drugs do not adequately treat the negative symptoms and cognitive
 dysfunction associated with schizophrenia.
     About Pharmacor from Decision Resources
     Pharmacor is a unique family of studies that assesses a host of market-
 impacting factors and analyzes the commercial outlook for drugs in research
 and development.
     About Decision Resources
     Decision Resources, Inc., ( is a world
 leader in research publications, advisory services, and consulting designed to
 help clients shape strategy, allocate resources, and master their chosen
     All company, brand, or product names contained in this document may be
 trademarks or registered trademarks of their respective holders.
     For more information, contact:
      Elizabeth Marshall
      Decision Resources, Inc.

SOURCE Decision Resources, Inc.